WO2021067657A1
|
|
Substituted carbazole compounds
|
WO2021067654A1
|
|
Indazole carboxamides as kinase inhibitors
|
WO2021067521A1
|
|
Compounds useful as immunomodulators
|
WO2021067326A1
|
|
Substituted bicyclic heteroaryl compounds
|
WO2021062018A1
|
|
Composite biomarker for cancer therapy
|
WO2021055994A1
|
|
Quantitative spatial profiling for lag-3 antagonist therapy
|
WO2021055698A1
|
|
Antibodies binding to vista at acidic ph
|
WO2021055651A1
|
|
Extended release dosage forms for tyk2 inhibitors
|
WO2021055306A1
|
|
Dual capture method for analysis of antibody-drug conjugates
|
WO2021050653A1
|
|
Pharmaceutical formulations of indoleamine 2, 3-dioxygenase inhibitors
|
WO2021041588A1
|
|
Substituted pyridopyrimidinonyl compounds useful as t cell activators
|
WO2021030379A1
|
|
Bicyclic heteroaryl compounds useful as irak4 inhibitors
|
WO2021024191A2
|
|
Combination treatments with benzodiazepinone compounds and phosphoinositide 3-kinase pathway inhibitors for treating cancer
|
WO2021026179A1
|
|
AGONISTS OF ROR GAMMAt
|
WO2021026181A1
|
|
Bicyclic heterocyclic compounds useful as irak4 inhibitors
|
WO2021021973A1
|
|
Methods of improving protein productivity in fed-batch cell cultures
|
WO2021016289A1
|
|
Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors
|
WO2021011727A1
|
|
PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS
|
WO2021011724A1
|
|
Tricyclic heteroaryl compounds useful as irak4 inhibitors
|
WO2021011681A1
|
|
Antibodies against human trem-1 and uses thereof
|